V dňoch 3. a 4. mája 2012 sa v Brne konal V. neuromuskulárny kongres, ktorý organizovala Neuromuskulární sekce České neurologické společnosti v spolupráci so Sekciou pre neuromuskulárne ochorenia Slovenskej neurologickej spoločnosti. Podujatie bolo súčasne XIII. konferenciou o neuromuskulárnych ochoreniach slovenskej Sekcie pre NMO. Program V. Neuromuskulárneho kongresu začal podvečer 2. mája 2012 pracovnou schôdzkou o vytváraní registrov neuromuskulárnych ochorení. Po tejto schôdzke nasledovalo spoločné stretnutie členov oboch národných výborov neuromuskulárnych sekcií.
- Publikační typ
- abstrakt z konference MeSH
- MeSH
- elektronystagmografie metody využití MeSH
- myasthenia gravis diagnóza MeSH
- pohyby očí MeSH
- Publikační typ
- kongresy MeSH
Aims. The aim of this study was to demonstrate that treatment with Timonil® retard (slow release carbomazepine - CBZ) twice daily results in flat plasma concentration time curves and thus offers effective seizure control combined with a convenient dosing schedule. Methods. Fifty-six patients with partial seizures were included in this open prospective, multicentre trial. Clinical efficacy in terms of monthly seizure frequency, carbamazepine plasma level profiling as well as safety and tolerance were assessed over a three-month treatment period. Results. Fifty-five patients were adequately controlled by slow-release CBZ (daily doses 450-1,800 mg) twice daily as monotherapy in = 38) or in combination with another anticonvulsant dmg (n = 17). On average, they experienced only one seizure per month. Plasma concentration fluctuations for CBZ and CBZ-10,11-epoxide were low, i.e. mean ± SD PTF(o-24h) 28.4 ± 13.2% and 35.2 ± 27.3%, respectively. Overall efficacy and safety of CBZ was rated „excellent" in 43 (77%) and 45 (80%) patients, respectively. No significant adverse effect or change in laboratory parameters were detected. Only one patient terminated the study prematurely due to lack of efficacy. Conclusions. These results indicate that treatment with slow-release CBZ (Timonil® retard) was effective, well tolerated and well perceived by patients with partial seizures.
- MeSH
- antikonvulziva aplikace a dávkování terapeutické užití MeSH
- dospělí MeSH
- epilepsie farmakoterapie MeSH
- farmakoterapie metody MeSH
- hodnocení léčiv MeSH
- karbamazepin aplikace a dávkování farmakokinetika terapeutické užití MeSH
- lidé MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- multicentrická studie MeSH
- MeSH
- cerebrovaskulární poruchy ultrasonografie MeSH
- dospělí MeSH
- echokardiografie transezofageální metody MeSH
- lidé MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
